Medigen Vaccine Biologics Corporation announced that it filed the New Drug Application of MVC EV71 Vaccine (Envacgen) to Drug Administration of Vietnam. New drug name or code: MVC EV71 Vaccine (Envacgen). Indication: It is suitable for active immunization of infants over 2 months to less than 6 years old children to prevent Enterovirus A71 infection. Current development stage: (1)Application submission/approval/disapproval/each of clinical trials
(include interim analysis): File the New Drug Application of MVC EV71 Vaccine (Envacgen) to Drug Administration of Vietnam. (2)Once disapproved by competent authority or each of clinical trials (include interim analysis) results less than statistically significant sense, the risks & the associated measures the Company may occur: N/A. (3)After obtaining official approval or the results of statistically significant sense, the future strategy: N/A. (4)Accumulated investment expenditure incurred: Based on business strategy considerations, it will not be disclosed for the time being.